TY - JOUR
T1 - Airmen and health-care providers’ attitudes toward the use of genomic sequencing in the US Air Force
T2 - findings from the MilSeq Project
AU - The MilSeq Project
AU - Pereira, Stacey
AU - Hsu, Rebecca L.
AU - Islam, Rubaiya
AU - Robinson, Jill Oliver
AU - Ramapriyan, Rishab
AU - Sirotich, Emily
AU - Maxwell, Megan D.
AU - Majumder, Mary
AU - Blout, Carrie L.
AU - Christensen, Kurt D.
AU - Mehlman, Maxwell
AU - Parasidis, Efthimios
AU - Gardner, Cubby L.
AU - Killian, Jacqueline M.
AU - De Castro, Mauricio
AU - Green, Robert C.
AU - Blout, Carrie L.
AU - Christensen, Kurt D.
AU - De Castro, Mauricio
AU - Green, Robert C.
AU - Killian, Jacqueline
AU - Krier, Joel B.
AU - Lane, William
AU - Lebo, Matthew S.
AU - Majumder, Mary
AU - Maxwell, Megan D.
AU - McGuire, Amy L.
AU - Parasidis, Efthimios
AU - Robinson, Jill O.
AU - Vassy, Jason L.
AU - Voss, Jameson
AU - Zettler, Bethany
AU - McGuire, Amy L.
N1 - Publisher Copyright:
© 2020, American College of Medical Genetics and Genomics.
PY - 2020/12
Y1 - 2020/12
N2 - Purpose: The use of genomic sequencing (GS) in military settings poses unique considerations, including the potential for GS to impact service members’ careers. The MilSeq Project investigated the use of GS in clinical care of active duty Airmen in the United States Air Force (USAF). Methods: We assessed perceived risks, benefits, and attitudes toward use of GS in the USAF among patient participants (n = 93) and health-care provider participants (HCPs) (n = 12) prior to receiving or disclosing GS results. Results: Participants agreed that there are health benefits associated with GS (90% patients, 75% HCPs), though more HCPs (75%) than patients (40%) agreed that there are risks (p = 0.048). The majority of both groups (67% HCPs, 77% patients) agreed that they trust the USAF with genetic information, but far fewer agreed that genetic information should be used to make decisions about deployment (5% patients, 17% HCPs) or duty assignments (3% patients, 17% HCPs). Despite their hesitancy, patients were supportive of the USAF testing for nondisease traits that could impact their duty performance. Eighty-seven percent of patients did not think their GS results would influence their career. Conclusion: Results suggest favorable attitudes toward the use of GS in the USAF when not used for deployment or assignment decisions.
AB - Purpose: The use of genomic sequencing (GS) in military settings poses unique considerations, including the potential for GS to impact service members’ careers. The MilSeq Project investigated the use of GS in clinical care of active duty Airmen in the United States Air Force (USAF). Methods: We assessed perceived risks, benefits, and attitudes toward use of GS in the USAF among patient participants (n = 93) and health-care provider participants (HCPs) (n = 12) prior to receiving or disclosing GS results. Results: Participants agreed that there are health benefits associated with GS (90% patients, 75% HCPs), though more HCPs (75%) than patients (40%) agreed that there are risks (p = 0.048). The majority of both groups (67% HCPs, 77% patients) agreed that they trust the USAF with genetic information, but far fewer agreed that genetic information should be used to make decisions about deployment (5% patients, 17% HCPs) or duty assignments (3% patients, 17% HCPs). Despite their hesitancy, patients were supportive of the USAF testing for nondisease traits that could impact their duty performance. Eighty-seven percent of patients did not think their GS results would influence their career. Conclusion: Results suggest favorable attitudes toward the use of GS in the USAF when not used for deployment or assignment decisions.
KW - ELSI
KW - exome sequencing
KW - genomics
KW - healthy populations
KW - military
UR - http://www.scopus.com/inward/record.url?scp=85092010025&partnerID=8YFLogxK
U2 - 10.1038/s41436-020-0928-9
DO - 10.1038/s41436-020-0928-9
M3 - Article
C2 - 32807975
AN - SCOPUS:85092010025
SN - 1098-3600
VL - 22
SP - 2003
EP - 2010
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 12
ER -